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Abstract
Background: No novel chemotherapeutic combinations have demonstrated superior efficacy to etoposide/cisplatin
(EP), a standard treatment regimen for extensive-stage small cell lung carcinoma (ES-SCLC) over the past decade.
We aimed to compare the efficacy and safety of belotecan/cisplatin (BP) and EP regimens in chemotherapy- and
radiotherapy-naïve patients with previously untreated ES-SCLC.
Methods: We conducted a multi-center, randomized, open-label, parallel-group, phase III clinical study. A total of
157 patients were recruited at 14 centers with 147 patients meeting the inclusion/exclusion criteria and randomized
to either BP (n = 71) or EP (n = 76) treatment arms. A non-inferior response rate (RR) in the BP arm, analyzed by
intent-to-treat analysis according to Response Evaluation Criteria in Solid Tumors version 1.0 criteria, was used as
the primary endpoint. The secondary endpoints were progression-free survival (PFS) and overall survival (OS).
Results: In the BP arm, one patient had a complete response, 41 had a partial response (PR), and 17 had stable
disease (SD). In the EP arm, 35 patients had PR and 28 had SD. The RR in the BP arm was non-inferior to the EP
regimen in patients with ES-SCLC (BP: 59.2 %, EP: 46.1 %, difference: 13.1 %, 90 % two-sided confidence interval: -0.
3–26.5, meeting the predefined non-inferiority criterion of -15.0 %). No significant differences in OS or PFS were
observed between the treatment arms. Hematologic toxicities, including grade 3/4 anemia and thrombocytopenia,
were significantly more prevalent in the BP arm than the EP arm.
Conclusions: The RR to the BP regimen was non-inferior to the EP regimen in chemotherapy- and radiotherapy-
naïve patients with previously untreated ES-SCLC. Hematologic toxicities were significantly more prevalent in the BP
group, indicating that BP should be used with care, particularly in patients with a poor performance status. Further
studies assessing PFS and OS are required to validate the superiority of the BP regimen.
Trial registration: ClinicalTrials.gov identifier NCT00826644. Date of Registration: January 21, 2009.
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and cisplatin; CI, Confidence interval; CMH, Cochran-mantel-haenzel; CR, Complete response; ECOG, Eastern
cooperative oncology group; EP, Etoposide and cisplatin; ES-SCLC, Extensive-stage small cell lung cancer; G-
CSF, Granulocyte colony-stimulating factor; HR, Hazards ratio; IP, Irinotecan and cisplatin; IRB, Institutional review
board; mITT, Modified intent-to-treat; MTD, Maximum tolerated dose; NSCLC, Non-small cell lung cancer; OS, Overall
survival; PD, Progressive disease; PFS, Progression-free survival; PP, Per-protocol; PR, Partial response; PS, Performance
status; RDI, Relative dose-intensity; RECIST, Response evaluation criteria in solid tumors; RR, Response rate;
SAE, Serious adverse events; SCLC, Small cell lung cancer; SD, Stable disease; TRD, Treatment-related death;
ULN, Upper limit of normal
Background
Lung cancer is one of the leading causes of cancer-related
death worldwide [1–3]. Small cell lung cancer (SCLC) ac-
counts for up to 20 % of all new cases of lung cancer and
deaths [3, 4]. Compared to non-small cell lung cancer
(NSCLC), SCLC is generally more aggressive, with de-
creased doubling times and faster growth rates. Moreover,
early widespread metastasis is a recognized feature of
SCLC [5]. Extensive-stage SCLC (ES-SCLC) refers to
SCLC metastasis to distant body regions. Since the mid-
1980s, no significant improvement in the survival of
patients with ES-SCLC has been observed; the median
overall survival (OS) is estimated at approximately
10 months [6–10]. Currently, a two-drug combination of
platinum and etoposide at doses associated with at least
moderate toxic effects is most commonly used to treat
ES-SCLC [11]. The overall response rates of 50 %–80 %
and complete response rates of 0 %–30 % have been re-
ported with this treatment approach [12, 13].
To date, a number of pharmacological agents have
been developed for the treatment of NSCLC. However,
no novel chemotherapeutic combinations have demon-
strated superior efficacy to etoposide/cisplatin (EP), a
standard treatment regimen, in the treatment of SCLC
over the past decade, although irinotecan/cisplatin (IP)
has been reported as an effective combination regimen
[10]. Belotecan {7-[2(N-isopropylamino) ethyl]-(20S)-
camptothecin} is a newly developed camptothecin
analogue. According to two multi-center phase IIa
studies, belotecan monotherapy is an effective modality
for the treatment of SCLC in chemotherapy-naïve pa-
tients [14, 15]. Moreover, multi-center phase II studies
have reported response rates (RR) higher than 70 % and
OS greater than 10 months in patients with ES-SCLC
receiving belotecan/cisplatin (BP) as a first-line treat-
ment regimen [16–18].
On the basis of the above mentioned information,
we conducted a multi-center, randomized, open-label,
parallel-group, phase III clinical study to compare the
efficacy and safety of BP and EP regimens in chemo-




Patients who met all of the following inclusion criteria
were enrolled in this trial: (1) aged between 19 and
80 years, (2) histologically or cytologically proven ES-
SCLC, (3) no past history of chemotherapy or radiother-
apy, (4) ≥1 measurable disease according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria version 1.0, (5) Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of ≤2, (6) a life
expectancy of ≥12 weeks, (7) adequate organ function
[absolute neutrophil count (ANC) ≥1,500/mm3, platelet
count ≥100,000/mm3, hemoglobin ≥9.0 g/dL, total
bilirubin level ≤1.5 mg/dL, aminotransferase ≤2-fold
upper limit of normal (ULN) or ≤3-fold ULN if dem-
onstrable liver metastases, alkaline phosphatase ≤2-
fold ULN, and creatinine ≤1.5 mg/dL or creatinine
clearance ≥60 mL/min].
The exclusion criteria were as follows: (1) severe bac-
terial infection, (2) malignancies other than basal cell
skin cancer or cervical carcinoma in situ, (3) brain me-
tastases, (4) women with child-bearing potential, and (5)
women who are pregnant or breast-feeding.
The study was approved by the Institutional Review Board
(IRB) of each medical institution. All patients provided a
written informed consent. The current study was registered
with ClinicalTrials.gov (Identifier: NCT00826644).
Dosing rationale and schedule
Patients were randomized to either EP or BP treatment
arms and stratified according to ECOG PS (0-1 vs. 2)
and age (<65 vs. ≥65 years) at a ratio of 1:1. A phase I
study was conducted to determine the maximum toler-
ated dose (MTD), toxicity, and dose-limiting toxicity of
BP; it showed that the MTD and recommended dose for
phase II studies was 0.5 mg/m2 on days 1–4 in combin-
ation with 60 mg/m2 cisplatin on day 1 at a 3-week
interval [19]. The BP regimen consisted of intravenous
belotecan 0.5 mg/m2 mixed with 100 mL of 5 % dextrose
over 30 min on day 1–4 and intravenous cisplatin
60 mg/m2 on day 1 of 3-week cycles. The EP regimen
consisted of etoposide 100 mg/m2 on days 1, 2 and 3
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and cisplatin 60 mg/m2 on day 1 of 3-week cycles. Both
regimens required hydration and administration of anti-
emetic drugs.
On day 1, the patients were treated if they showed an
ANC ≥1,500/mm3, platelet count ≥100,000/mm3, and
creatinine clearance ≥60 mL/min. In addition, the pa-
tients were given recombinant human granulocyte
colony-stimulating factor (G-CSF) to improve ANC ac-
cording to clinical judgment. Subsequent treatments
were delayed on a weekly basis until recovery of ANC
in cases of G-CSF treatment failure. The patients
dropped out of the study if the treatment was delayed
by more than 2 weeks. With respect to the dose of the
subsequent treatment, the patients were given un-
adjusted treatment doses upon recovery of ANC to
≥1,500/mm3 and a platelet count ≥100,000/mm3. In the
patients achieving a recovery of ANC to 1,000–1,500/
mm3 and a platelet count to 75,000–100,000/mm3, sub-
sequent treatment doses were reduced by 20 %. In pa-
tients with ANC <500/mm3, platelet count <25,000/
mm3, or febrile neutropenia during treatment, subse-
quent treatment doses were reduced by 20 %. Cisplatin
doses were not adjusted in patients with decreases in
creatine clearance to ≥60 mL/min from baseline.
Cisplatin doses were reduced by 50 % in patients with
creatinine clearance of 30–60 mL/min. Cisplatin was
discontinued in patients with decreases in creatinine
clearance to ≤30 mL/min.
Patient evaluation
The patients were evaluated at baseline based on their
medical history, physical examination, imaging studies,
complete blood counts, and serum biochemistry. The re-
sponse was assessed by computed tomography (CT)
every two treatment cycles at follow-up visits. After the
completion of chemotherapy, CT scans were performed
every three months until evidence or suspicion of dis-
ease progression. The treatment response was centrally
evaluated independently according to RECIST version
1.0 criteria as follows: (1) complete response (CR), dis-
appearance of all clinical and radiological evidence of
the tumor; (2) partial response (PR), decrease of 30 % or
more in the sum of longest diameters of all target meas-
urable lesions; (3) progressive disease (PD), increase of
more than 20 % of the sum of longest diameters of all
target measurable lesions or the appearance of new le-
sions; and (4) stable disease (SD), all other circum-
stances. The patients eligible for response evaluation
were evaluated at a minimum interval of 4 weeks to
confirm CR or PR. Adverse events (AEs) were graded




Per-protocol (PP) population was defined patients who
completed two cycles of chemotherapy in accordance
with the protocol. Modified Intent-to-treat (mITT)
population was defined as patients randomized and
treated with at least one cycle of chemotherapy. mITT
analysis was used to assess non-inferiority of RR in the
BP arm as the primary endpoint according to RECIST
1.0 criteria. The secondary endpoints were progression-
free survival (PFS) and OS. Subgroup analysis of the
mITT population was performed to assess the associa-
tions between RR and ECOG PS, age, and body weight.
Safety endpoints
The safety population comprised all patients eligible for
safety analysis. The occurrence of toxicities and adverse
effects were evaluated throughout the study period
through the measurement of vital signs, physical examin-
ation, and clinical laboratory tests. The safety endpoints
were adverse drug reactions (ADRs), serious adverse
events (SAEs), and treatment-related death (TRD).
Statistical analyses
To determine the sample size, we estimated an RR of
71 % for the BP arm [14, 15, 19] and 66 % for the EP
arm [6, 13, 20], considering a non-inferiority margin of
−15 % at a power of 80 % with a one-sided error (α) =
0.05 [21]. In addition, we assumed a dropout rate of
10 % during the follow-up period. Thus, we aimed to en-
roll a total of 150 patients (n = 150) in the present study.
The baseline and clinical characteristics of the patients
were expressed as median and range. The Student’s t-
test and chi-square test were used to compare two treat-
ment arms, as appropriate. Two-sided 90 % confidence
intervals (CIs) were calculated for the difference in the
RR between the two treatment arms without corrections
for continuity, as described by Newcombe [21]. The
Cochran–Mantel–Haenszel (CMH) test was performed
in patients who met the criteria for non-inferiority with
consideration of the stratification factors. Thus, we
attempted to analyze the difference in RR between the
two treatment arms using Fisher’s exact test. PFS was
defined as the time from randomization to clinical or
radiological progression or death. OS was defined as the
time from randomization to death from any cause. If the
patient was lost to follow up or an event (disease pro-
gression or death) did not occur until study termination,
the patient was censored at the time of last contact. PFS
and OS were analyzed using the Kaplan–Meier methods.
Results
Patient groups
A total of 157 patients were recruited at 14 centers
across Korea from January 2009 to January 2013. Of
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these, 147 patients met the inclusion/exclusion criteria
of this study and were randomized to the BP (n = 71) or
EP (n = 76) arms. The number of the patients in the
mITT, PP, and safety populations were 71, 57, and 70 in
the BP arm and 76, 63, and 77 in the EP arm, respect-
ively (Fig. 1).
Patient baseline and clinical characteristics
No significant differences in the median age, median
male-to-female ratio, median body surface area, or me-
dian ECOG PS were observed between the treatment
arms (Table 1). A significant difference in the median
body mass index was observed between the treatment
arms (p < 0.05).
The proportion of the patients receiving more than
four cycles of chemotherapy was 67.1 % in the BP arm
and 63.7 % in the EP arm. The mean number of chemo-
therapy cycles was 3.9 in the BP arm and 4.1 in the EP
arm. In the BP arm, the mean delivered dose of belote-
can and cisplatin was 0.45 mg/m2 (90.0 % of planned
dose) and 56.8 mg/m2 (94.6 % of planned dose), respect-
ively. In the EP arm, the mean delivered dose of etopo-
side and cisplatin was 93.8 mg/m2 (93.8 % of planned
dose) and 58.6 mg/m2 (97.7 % of planned dose), respect-
ively. The relative dose intensity (RDI) was calculated by
dividing the intensity of the delivered dose by that of the
standard dose. A significantly lower RDI was observed
in the BP arm than that in the EP arm (0.79 ± 0.14 vs.
0.86 ± 0.13, p = 0.001).
Efficacy endpoints
Response rates
According to the mITT analysis, the RR was 59.2 %
in the BP arm and 46.1 % in the EP arm (Table 2 &
Fig. 2). The lower limit of the two-sided 90 % CI was
greater than the non-inferiority margin (−0.3 vs.
−15.0). This indicates that the BP regimen was non-
inferior to the EP regimen with respect to the RR in
patients with ES-SCLC.
According to the PP analysis, an 18.0 % difference in
the RR was demonstrated between the two treatment
arms (90 % CI: 3.7–32.3). In addition, no significant dif-
ferences in the RRs between the two treatment arms in
either the mITT or PP groups were observed according
to the CMH test.
Overall survival and progression-free survival
No significant differences in OS or PFS were observed
between the treatment arms. The median OS was
360 days (95 % CI: 285–482) in the BP arm and 305 days
(95 % CI: 232–343) in the EP arm (Log-Rank p = 0.210,
Fig. 3). In addition, the median PFS was 190 days (95 %
CI: 148–219) in the BP arm and 172 days (95 % CI:
144–195) in the EP arm (Log-Rank p = 0.369, Fig. 3).
Fig. 1 Disposition of the study patients. Of the 157 patients we recruited at a total of 14 centers, 147 met inclusion/exclusion criteria and then
randomized to either the BP arm (n = 71) or the EP arm (n = 76). In the BP arm, the number of the patients of the mITT set, the PP set and the
safety set were 71, 57 and 70, respectively. In the EP arm, these values were 76, 63 and 77 in the corresponding order
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Subgroup analysis
In the BP arm, the RR was 63.3 % in patients with
ECOG PS 0-1 (n = 60) and 36.4 % in those with ECOG
PS 2 (n = 11). In the EP arm, the RR was 52.7 % in pa-
tients with ECOG PS 0–1 (n = 55) and 28.6 % in those
with ECOG PS 2 (n = 21). In addition, the RR was
66.7 % in patients aged ≤65 years (n = 30) and 53.7 % in
those aged ≥65 years (n = 41) in the BP arm. In the
EP arm, the RR was 57.8 % in patients aged ≤65 years
(n = 33) and 37.2 % in those aged ≥65 years (n = 43).
Furthermore, the RR was 60.0 % in patients weighing
less than 62.5 kg (n = 30) and 58.5 % in those weigh-
ing more than 62.5 kg (n = 41) in the BP arm. In the
EP arm, the RR was 45.2 % in patients weighing less
than 62.5 kg (n = 42) and 47.1 % in those weighing
more than 62.5 kg (n = 34).
Safety endpoints
In the present study, all 147 included patients were
eligible for safety analysis. No significant differences in
ADRs or TRD were observed between the treatment
arms (98.6 % vs. 92.2 %, p = 0.119 and 12.9 % vs. 10.4 %,
p = 0.797, respectively). However, the incidence of SAEs
was significantly higher in the BP arm (42/70 cases,
60.0 %) than those in the EP arm (31/77 cases,
40.3 %, p = 0.021). Hematologic toxicities were more
prevalent in this study than non-hematologic toxicities.
Grade 3/4 anemia (34.3 %) and thrombocytopenia
(54.3 %) were significantly more prevalent in the BP arm
Table 1 Patient demographics of modified intent-to-treat population
Characteristic Belotecan/Cisplatin (n = 71) Etoposide/Cisplatin (n = 76) p value





Male 62 87.3 65 85.5
Female 9 12.7 11 14.5
Body mass index, kg/m2 .004
Median 23.5 22.0
Range 15.1–30.4 15.0–30.8
Body surface area, m2 .055
Median 1.71 1.65
Range 1.30–1.99 1.26–2.06
ECOG performance status .200
0 23 32.4 20 26.3
1 37 52.1 35 46.1
2 11 15.5 21 27.6
Abbreviation: ECOG Eastern cooperative oncology group
Table 2 Best overall response of modified intent-to-treat and
per protocol population
Modified intent-to-treat population
Response BP (n = 71) EP (n = 76) Difference 90 % CI P value by
CMH test
No. % No. %
CR 1 1.4 0 0
PR 41 57.7 35 46.1
SD 17 23.9 28 36.8
PD 4 5.6 5 6.6
NE 8 11.3 8 10.5
CR + PR 42 59.2 35 46.1 13.1 −0.3 to 26.5 .214
CR + PR
+ SD
59 83.1 63 82.9 0.2 −10.0 to 10.4 .826
Per protocol population
Response BP (n = 57) EP (n = 63) Difference 90 % CI P value by
CMH test
No. % No. %
CR 1 1.8 0 0
PR 40 70.2 34 54.0
SD 9 15.8 21 33.3
PD 3 5.3 3 4.8
NE 4 7.0 5 7.9
CR + PR 41 71.9 34 54.0 18.0 3.7 to 32.2 .061
CR + PR
+ SD
50 87.7 55 87.3 0.4 −0.95 to 10.4 .978
Abbreviation: BP belotecan/cisplatin, EP etoposide/cisplatin, CI Confidence
interval, CMH Cochran-Mantel-Haenzel, CR complete response, PR partial
response, SD stable disease, PD progressive disease, NE non-evaluable cases
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than those in the EP arm. No significant difference in the
incidence of non-hematologic toxicities was observed be-
tween the treatment arms. Grade 3/4 infection and hypo-
natremia occurred in approximately 10 % of the patients
in both treatment arms. Nearly all the non-hematologic
toxicities were of grade 1/2 severity and could be treated
successfully (Table 3).
Discussion
This is the first study to evaluate the non-inferiority of
the BP regimen compared to the EP regimen as a first-
line treatment in patients with previously untreated ES-
SCLC. Compared to the EP regimen, the RR of the BP
regimen was non-inferior in the mITT population and
better in the PP population. Grade 3/4 anemia and
thrombocytopenia were more prevalent in the BP arm
than those in the EP arm. In addition, the RDI was sig-
nificantly lower in the BP arm than that in the EP arm.
However, no significant differences in OS or PFS were
observed between the treatment arms.
Over recent decades, EP has been considered the gold-
standard treatment for ES-SCLC. In 2002, a phase III
Fig. 2 Efficacy endpoints of modified intent-to-treat (mITT) and per protocol (PP) population. The BP group is not inferior to the EP group with
regards to the response rate (between group difference 13.1 %, 90 % two-sided confidence interval -0.3 to 26.5, meeting the predefined non-
inferiority criterion of -15.0 %) in mITT population. The response of the BP group was superior in PP population
Fig. 3 Overall survival and progression-free survival on Kaplan–Meier analysis. (a) There were no significant differences in the OS and PFS between the
two treatment arms. That is, the median OS was 360 days (95 % CI: 285–482) in the BP arm and 305 days (95 % CI: 232–343) in the EP arm (Log-Rank
p = 0.210). (b) The median PFS was 190 days (95 % CI: 148-219) in the BP arm and 172 days (95 % CI: 144–195) in the EP arm (Log-Rank p = 0.369)
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trial was conducted by the Japan Clinical Oncology
Group; it demonstrated the superiority of IP over EP in
patients with ES-SCLC [10]. However, two subsequent
randomized phase III trials failed to confirm the super-
iority of IP over EP in North American and Australian
populations [7, 8]. Noda et al. reported that the RR and
median OS were 65 % and 12.8 months in the IP arm,
respectively [10]. Our results were consistent with previ-
ous studies, demonstrating a similar efficacy based on an
RR of 60 % and a median OS of 12.9 months. However,
we found a higher proportion of patients with ECOG PS
2 than the study by Noda et al. (16 % vs. 8 %). Moreover,
the RR in the present study was approximately 10 %
lower than previous phase II trials enrolling a smaller
number of patients [16–18]. To date, Lim et al. have re-
ported the highest RR (73.8 %) with the use of the BP
regimen [18]. Lee et al. reported a median PFS of
6.9 months and a median OS of 19.2 months in patients
receiving the BP regimen [16]. In the current study, the
degree of the difference in the RR between the two treat-
ment arms was higher in the PP population than the
mITT population (18.0 % vs. 13.1 %). Moreover, our re-
sults also showed a slightly higher RR in patients with
ECOG PS 0–1 (63.3 %) and those aged ≤65 years
(66.7 %). These results indicate that the BP regimen may
have a greater utility in younger patients with a good
performance status.
In the present study, favorable rates of non-
hematologic toxicities were observed in the BP arm
according to the safety analysis. We found that 2.9 %
of the patients in the BP arm developed grade 3/4
diarrhea; this may be considerably lower than the in-
cidence of non-hematologic toxicities reported in the
IP arm of previous trials (16 %–19 %) [8, 10]. In the
BP arm, neutropenia was one of the most frequent
hematologic toxicities, 77 % of which were of grade 3
or 4 severity. Grade 3/4 febrile neutropenia occurred
in 15.7 % of patients in the BP arm. Of these, one
patient died of pneumonia. No significant differences
in the incidences of neutropenia or febrile neutro-
penia were observed between the treatment arms. In
the EP arm, there were five cases of treatment-related
deaths due to pneumonia or sepsis. However, grade
3/4 anemia (34.3 % vs. 13.0 %, p = 0.003) and
thrombocytopenia (54.3 % vs. 16.9 %, p < 0.001) were
significantly more prevalent in the BP arm than the
EP arm. The prophylactic use of G-CSF or 5 %–10 %
reductions in chemotherapeutic doses may be consid-
ered to prevent hematologic toxicities. In the present
study, the mean RDI was 7 % lower in the BP arm
Table 3 Hematologic and non-hematologic toxicities of safety population
BP Group (n = 70) EP Group (n = 77) P†
Gradea, n (%) Gradea, n (%)
1 2 3 4 ≥3 1 2 3 4 ≥ 3
Febrile neutropenia 0(0.0) 0(0.0) 7(10.0) 4(5.7) 11(15.7) 0(0.0) 0(0.0) 6(7.8) 0(0.0) 6(7.8) 0.196
Anemia 3(4.3) 30(42.9) 21(30.0) 3(4.3) 24(34.3) 13(16.9) 33(42.9) 10(13.0) 0(0.0) 10(13.0) 0.003
Leukopenia 3(4.3) 13(18.6) 23(32.9) 19(27.1) 42(60.0) 5(6.5) 17(22.1) 25(32.5) 10(13.0) 35(45.5) 0.098
Neutropenia 1(1.4) 3(4.3) 11(15.7) 43(61.4) 54(77.1) 2(2.6) 9(11.7) 14(18.2) 38(49.4) 52(67.5) 0.204
Thrombocytopenia 2(2.9) 14(20.0) 21(30.0) 17(24.3) 38(54.3) 13(16.9) 4(5.2) 7(9.1) 6(7.8) 13(16.9) < 0.001
Anorexia 7(10.0) 13(18.6) 1(1.4) 0(0.0) 1(1.4) 6(7.8) 9(11.7) 1(1.3) 0(0.0) 1(1.3) 1.000
Nausea 12(17.1) 12(17.1) 2(2.9) 0(0.0) 2(2.9) 10(13.0) 7(9.1) 2(2.6) 0(0.0) 2(2.6) 1.000
Vomiting 8(11.4) 5(7.1) 1(1.4) 0(0.0) 1(1.4) 4(5.2) 3(3.9) 0(0.0) 0(0.0) 0(0.0) 0.473
Weight loss 0(0.0) 0(0.0) 1(1.4) 0(0.0) 1(1.4) 0(0.0) 3(3.9) 1(1.3) 0(0.0) 1(1.3) 1.000
Anxiety 1(1.4) 2(2.9) 2(2.9) 0(0.0) 2(2.9) 3(3.9) 3(3.9) 0(0.0) 0(0.0) 0(0.0) 0.473
Diarrhea 14(20.0) 7(10.0) 2(2.9) 0(0.0) 2(2.9) 8(10.4) 2(2.6) 1(1.3) 0(0.0) 1(1.3) 0.605
Fatigue 8(11.4) 11(15.7) 4(5.2) 0(0.0) 4(5.2) 18(23.4) 12(15.6) 3(3.9) 0(0.0) 3(3.9) 0.498
Infection 0(0.0) 0(0.0) 9(12.9) 3(4.3) 13(18.6) 0(0.0) 4(5.2) 5(6.5) 0(0.0) 10(13.0) 0.577
Hepatic dysfunction 1(1.4) 5(7.1) 2(2.9) 0(0.0) 2(2.9) 4(5.2) 3(3.9) 4(5.2) 2(2.6) 6(7.8) 0.621
Hyperglycemia 0(0.0) 4(5.7) 2(2.9) 0(0.0) 2(2.9) 0(0.0) 3(3.9) 4(5.2) 1(1.3) 5(6.5) 0.446
Hyponatremia 1(1.4) 0(0.0) 6(8.6) 6(8.6) 12(17.1) 0(0.0) 1(1.3) 6(7.8) 3(3.9) 9(11.7) 0.631
Hyperkalemia 0(0.0) 0(0.0) 2(2.9) 0(0.0) 2(2.9) 0(0.0) 1(1.3) 3(3.9) 0(0.0) 3(3.9) 1.000
Hypokalemia 0(0.0) 0(0.0) 3(4.3) 0(0.0) 3(4.3) 1(1.3) 0(0.0) 1(1.3) 0(0.0) 1(1.3) 0.347
aGrade means the maximum grade of toxicity. Grade 5 toxicities were developed by infection (1 patient in BP arm and 5 patients in EP arm) and disease
progression (2 patients in EP arm)
†P value was calculated by Fisher’s exact test for grade ≥ 3 toxicity
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than that in the EP arm (0.79 ± 0.14 vs. 0.86 ± 0.13).
A previous phase II study found that more than half
of the patients presented with grade 4 neutropenia
and reported an RDI of 70.1 % in the belotecan regi-
men and 83.0 % in the cisplatin regimen. As a result
of the findings of this trial, the recommended BP
regimen dose of BP was reduced by 25 % (0.5 mg/m2
for 3 days) [17].
A first limitation of this study is the non-inferiority
design of this trial. Because the experimental arm
demonstrated a higher hematological toxicity, superior
results are required to justify the use of the experi-
mental treatment. Because the analysis of the PP
group demonstrated a better response rate with the
BP regimen than the EP regimen, further studies are
required to validate the superior efficacy of the BP
regimen. Second limitation is the significance level in
the statistical design. Although setting the significance
level for one-sided, non-inferiority trials is recom-
mended at 0.025, we chose the alpha level at 0.05 to
accomplish the trial within reasonable time span.
Third, the ORR which was primary endpoint of this
study may not be sufficiently correlated to patient’s
outcome. We selected ORR instead of OS because
this study was conducted with small sample size.
Fourth, the ITT set of this study was mITT popula-
tion as 9 randomized patients are excluded because
they did not receive the randomly assigned regimen.
They were three subjects who withdrew informed
consents and six who did not meet inclusion criteria.
If a subject who actually did not receive any treat-
ment is included as a subject who received treatment,
then it indicates very little about the efficacy of the
treatment [22]. So we defined mITT population as
patients randomized and treated with at least one
cycle of chemotherapy. Fifth, the interpretation of
subgroup analyses for ECOG PS score, age and body
weight was limited because of the issue of multiple
comparisons. Finally, as the open-label nature of this
study could be regarded as a flaw in a non-inferiority
study. However, because these two regimens have dif-
ferent infusion protocols, we were unable to design
this study as a blinded trial.
Conclusions
The results of this trial indicate that the RR with the BP
regimen is non-inferior to the EP regimen in chemother-
apy- and radiotherapy-naïve patients with previously
untreated ES-SCLC. However, hematologic toxicities, in-
cluding anemia and thrombocytopenia, were more preva-
lent in the BP arm. These findings strongly suggest that
clinicians should be careful in prescribing the BP regimen
to elderly patients or those with a poor performance status
for the purpose of preventing hematologic toxicities.
Further studies evaluating PFS and OS are required to
validate the superiority of the BP regimen.
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